Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,702 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CT Clear all
Recruiting Not applicable Interventional

Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients

NCT07379138
View directory record Official record
Conditions
Melanoma
Interventions
Best Practice, Cognitive Behavior Therapy, Electronic Health Record Review, Questionnaire Administration
Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

NCT00416455
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
Radiation · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Phase 1 Interventional

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

NCT05711615
View directory record Official record
Conditions
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

NCT02423863
View directory record Official record
Conditions
Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
Interventions
Hiltonol
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer

NCT01986738
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Standard Radiation Therapy, Active Breathing Control Device (ABC), Computed Tomography Scan (CT)
Radiation · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

NCT00082758
View directory record Official record
Conditions
Neuroblastoma
Interventions
hu14.18-Interleukin-2 fusion protein
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
69
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Verification of Imaging System PCD-1000A

NCT04024748
View directory record Official record
Conditions
Cancer Patients
Interventions
PET/CT imaging
Device
Lead sponsor
Canon Medical Systems, USA
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Henderson, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional

Stress Echocardiography and Heart Computed Tomography (CT) Scan in Emergency Department Patients With Chest Pain

NCT01384448
View directory record Official record
Conditions
Chest Pain, Angina, Angina Pectoris, Coronary Artery Disease
Interventions
Stress Echocardiography, Coronary CT Angiography
Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
30 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 17, 2026, 5:14 AM EDT
Withdrawn Phase 1 Interventional

Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer

NCT03029871
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage I
Interventions
Ad5-yCD/mutTKSR39rep-ADP Adenovirus
Biological
Lead sponsor
Benjamin Movsas, M.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Early Phase 1 Interventional

NIH CCR2 AAA Study

NCT04586452
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA), No Abdominal Aortic Aneurysm (Non-AAA)
Interventions
AAA Group (Aim 3A), Non-AAA Group, Ex Vivo Human AAA Specimens (Aim 2A), Relationship between radiotracer and CCR2 (Aim 2B), AAA Group (Aim 3B-Reproducibility)
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

NCT06400238
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Suspended Phase 1 Interventional

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

NCT05791448
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, RNA Transcription Modulator AU-409
Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Phase 3 Interventional

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT05976763
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection, Questionnaire Administration
Drug · Biological · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
60 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
238
States / cities
Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 185 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional Results available

Dual Energy Cone-Beam Computed Tomography (DE-CBCT) Assessment of Jaw Bone Density

NCT04686084
View directory record Official record
Conditions
Dental Diseases
Interventions
Dual-energy computed tomography scan
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Followup of Glenoid Fix Utilizing Auto Bone Graft in Shoulder Replacement

NCT00670852
View directory record Official record
Conditions
Arthritis
Interventions
X-rays and CT scan
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

NCT05779943
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography, Computed Tomography
Drug · Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Early Phase 1 Interventional

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

NCT02145143
View directory record Official record
Conditions
Thyroid Carcinoma
Interventions
Vemurafenib, serial 124I PET/CT, thyrotropin alpha
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer

NCT00924313
View directory record Official record
Conditions
Prostate Cancer
Interventions
(C-11 Acetate)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Not applicable Interventional

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

NCT06572423
View directory record Official record
Conditions
Head and Neck Carcinoma, Localized Head and Neck Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma
Interventions
Personalized ultrafractionated stereotactic adaptive radiotherapy, Volume Modulated Arc Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Best Practice, University of Washington Quality of Life Scale, Version 4, Functional Assessment of Cancer Therapy-Head & Neck
Procedure · Radiation · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab In Central Nervous System Metastases

NCT02886585
View directory record Official record
Conditions
Brain Metastases
Interventions
Pembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

NCT05688215
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Core Biopsy, Fluorouracil, Irinotecan, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quemliclustat, Zimberelimab
Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Not yet recruiting Phase 3 Interventional

Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall

NCT07823491
View directory record Official record
Conditions
Resectable Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biospecimen Collection, Computed Tomography, Doxorubicin, Ifosfamide, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pembrolizumab, Questionnaire Administration, Surgical Procedure, Transthoracic Echocardiography Test
Procedure · Drug · Radiation + 2 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Early Phase 1 Interventional

18F-DOPA-PET in Planning Surgery in Patients With Gliomas

NCT02020720
View directory record Official record
Conditions
Malignant Glioma, Recurrent Brain Neoplasm
Interventions
Biopsy, Computed Tomography, Diffusion Weighted Imaging, Fluorine F 18 Fluorodopa, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Conventional Surgery
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma

NCT02541123
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Blood draw
Other
Lead sponsor
Banyan Biomarkers, Inc
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Gainesville, Florida • Orlando, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 17, 2026, 5:14 AM EDT